Jian Liang1, Fengyu Liu1, Yaoqiang Yang1, Xing Li2, Guangmou Cai1, Jianxuan Cao1, Bo Zhang1. 1. Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology) Shenzhen 518020, Guangdong, China. 2. School of Medicine, Southern University of Science and Technology Shenzhen 518055, Guangdong, China.
Abstract
BACKGROUND: Among various glioma types, glioblastoma multiforme (GBM) is one of those with the highest malignancy. Although overexpression of eukaryotic translation initiation factor 6 (eIF6), a factor that regulates protein translation initiation, is believed to promote tumor development, its function and potential molecular mechanisms in glioma progression remain uncharacterized. Consequently, we evaluated its diagnostic and prognostic utility in GBM patients. METHODS: Sample data from two databases, The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), were utilized to investigate the role of eIF6 as well as its mechanism of action in gliomas. We analyzed eIF6 expression in normal tissues as well as cancerous samples of different stages of glioma. The diagnostic and prognostic value of eIF6 were analyzed using the Receiver Operating Characteristic Curve (ROC) and Kaplan-Meier analysis, respectively. Furthermore, its underlying molecular mechanism in GBM was further revealed by gene set enrichment analysis (GSEA). RESULTS: Transcriptome data analyses of the two databases showed that eIF6 was upregulated in glioma tissues compared with normal counterparts. eIF6 was at high levels in WHO grade IV gliomas versus grade II and III gliomas (P<0.05). In addition, eIF6 was highly expressed in elderly and Asian glioma patients. Furthermore, eIF6 expression was found to be lower in isocitrate dehydrogenase (IDH)-mutated tumors. Patients with high eIF6 level presented shorter overall survival than cases with low eIF6 level (P<0.05), and eIF6 had favorable accuracy in predicting the prognosis of glioma patients. GSEA revealed that high eIF6 expression was mainly concentrated in cell cycle and DNA repair related pathways. CONCLUSIONS: eIF6 is highly expressed in gliomas and positively associated with the degree of malignancy. Patients with high eIF6 expression present poor survival. Therefore, eIF6 has the potential to be a diagnostic biomarker and a potential therapeutic target for glioma development and GBM. AJTR
BACKGROUND: Among various glioma types, glioblastoma multiforme (GBM) is one of those with the highest malignancy. Although overexpression of eukaryotic translation initiation factor 6 (eIF6), a factor that regulates protein translation initiation, is believed to promote tumor development, its function and potential molecular mechanisms in glioma progression remain uncharacterized. Consequently, we evaluated its diagnostic and prognostic utility in GBM patients. METHODS: Sample data from two databases, The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), were utilized to investigate the role of eIF6 as well as its mechanism of action in gliomas. We analyzed eIF6 expression in normal tissues as well as cancerous samples of different stages of glioma. The diagnostic and prognostic value of eIF6 were analyzed using the Receiver Operating Characteristic Curve (ROC) and Kaplan-Meier analysis, respectively. Furthermore, its underlying molecular mechanism in GBM was further revealed by gene set enrichment analysis (GSEA). RESULTS: Transcriptome data analyses of the two databases showed that eIF6 was upregulated in glioma tissues compared with normal counterparts. eIF6 was at high levels in WHO grade IV gliomas versus grade II and III gliomas (P<0.05). In addition, eIF6 was highly expressed in elderly and Asian glioma patients. Furthermore, eIF6 expression was found to be lower in isocitrate dehydrogenase (IDH)-mutated tumors. Patients with high eIF6 level presented shorter overall survival than cases with low eIF6 level (P<0.05), and eIF6 had favorable accuracy in predicting the prognosis of glioma patients. GSEA revealed that high eIF6 expression was mainly concentrated in cell cycle and DNA repair related pathways. CONCLUSIONS: eIF6 is highly expressed in gliomas and positively associated with the degree of malignancy. Patients with high eIF6 expression present poor survival. Therefore, eIF6 has the potential to be a diagnostic biomarker and a potential therapeutic target for glioma development and GBM. AJTR
Authors: Nadine Gantenbein; Eva Bernhart; Ines Anders; Nicole Golob-Schwarzl; Stefanie Krassnig; Christina Wodlej; Luka Brcic; Joerg Lindenmann; Nicole Fink-Neuboeck; Franz Gollowitsch; Elvira Stacher-Priehse; Martin Asslaber; Margit Gogg-Kamerer; Jana Rolff; Jens Hoffmann; Alessandra Silvestri; Christian Regenbrecht; Christoph Reinhard; Anna-Maria Pehserl; Martin Pichler; Olga Sokolova; Michael Naumann; Valentin Mitterer; Brigitte Pertschy; Helmut Bergler; Helmut Popper; Wolfgang Sattler; Johannes Haybaeck Journal: Eur J Cancer Date: 2018-08-01 Impact factor: 9.162
Authors: Nicole Golob-Schwarzl; Philip Puchas; Margit Gogg-Kamerer; Wilko Weichert; Benjamin Göppert; Johannes Haybaeck Journal: Anticancer Res Date: 2020-06 Impact factor: 2.480
Authors: Maria Anna Smolle; Piotr Czapiewski; Sylwia Lapińska-Szumczyk; Hanna Majewska; Anna Supernat; Anna Zaczek; Wojciech Biernat; Nicole Golob-Schwarzl; Johannes Haybaeck Journal: Int J Mol Sci Date: 2019-12-06 Impact factor: 5.923